New combo therapy shows promise for leukemia relapse after transplant
NCT ID NCT02684162
First seen Nov 06, 2025 · Last updated May 22, 2026 · Updated 29 times
Summary
This study tested a drug called guadecitabine combined with donor white blood cell infusions in 55 adults whose leukemia or MDS came back after a stem cell transplant. The goal was to see if the drug could help the donor cells fight the cancer more effectively. The treatment aims to control the disease, but lifelong monitoring and potential ongoing therapy may still be needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.